Diagnosis and Treatment > Investigation > Laparoscopy

You are looking at 1 - 3 of 3 items

Chloe Broughton Southmead Hospital, North Bristol NHS Trust, Westbury-on-Trym, Bristol, UK

Search for other papers by Chloe Broughton in
Google Scholar
PubMed
Close
,
Jane Mears Southmead Hospital, North Bristol NHS Trust, Westbury-on-Trym, Bristol, UK

Search for other papers by Jane Mears in
Google Scholar
PubMed
Close
,
Adam Williams Southmead Hospital, North Bristol NHS Trust, Westbury-on-Trym, Bristol, UK

Search for other papers by Adam Williams in
Google Scholar
PubMed
Close
, and
Kathryn Lonnen Southmead Hospital, North Bristol NHS Trust, Westbury-on-Trym, Bristol, UK

Search for other papers by Kathryn Lonnen in
Google Scholar
PubMed
Close

Summary

Pituitary adenomas can be classified as functioning or non-functioning adenomas. Approximately 64% of clinically non-functioning pituitary adenomas are found to be gonadotroph adenomas on immunohistochemistry. There are reported cases of gonadotroph adenomas causing clinical symptoms, but this is unusual. We present the case of a 36-year-old female with abdominal pain. Multiple large ovarian cysts were identified on ultrasound requiring bilateral cystectomy. Despite this, the cysts recurred resulting in further abdominal pain, ovarian torsion and right oophorectomy and salpingectomy. On her 3rd admission with abdominal pain, she was found to have a rectus sheath mass which was resected and histologically confirmed to be fibromatosis. Endocrine investigations revealed elevated oestradiol, follicle-stimulating hormone (FSH) at the upper limit of the normal range and a suppressed luteinising hormone (LH). Prolactin was mildly elevated. A diagnosis of an FSH-secreting pituitary adenoma was considered and a pituitary MRI revealed a 1.5 cm macroadenoma. She underwent transphenoidal surgery which led to resolution of her symptoms and normalisation of her biochemistry. Subsequent pelvic ultrasound showed normal ovarian follicular development. Clinically functioning gonadotroph adenomas are rare, but should be considered in women presenting with menstrual irregularities, large or recurrent ovarian cysts, ovarian hyperstimulation syndrome and fibromatosis. Transphenoidal surgery is the first-line treatment with the aim of achieving complete remission.

Learning points:

  • Pituitary gonadotroph adenomas are usually clinically non-functioning, but in rare cases can cause clinical symptoms.

  • A diagnosis of a functioning gonadotroph adenoma should be considered in women presenting with un-explained ovarian hyperstimulation and/or fibromatosis.

  • In women with functioning gonadotroph adenomas, the main biochemical finding is elevated oestradiol levels. Serum FSH levels can be normal or mildly elevated. Serum LH levels are usually suppressed.

  • Transphenoidal surgery is the first-line treatment for patients with functioning gonadotroph adenomas, with the aim of achieving complete remission.

Open access
Elise Flynn Austin Health, Heidelberg, Victoria, Australia

Search for other papers by Elise Flynn in
Google Scholar
PubMed
Close
,
Sara Baqar Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Sara Baqar in
Google Scholar
PubMed
Close
,
Dorothy Liu University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Dorothy Liu in
Google Scholar
PubMed
Close
,
Elif I Ekinci Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Elif I Ekinci in
Google Scholar
PubMed
Close
,
Stephen Farrell Austin Health, Heidelberg, Victoria, Australia

Search for other papers by Stephen Farrell in
Google Scholar
PubMed
Close
,
Jeffrey D Zajac Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Close
,
Mario De Luise Austin Health, Heidelberg, Victoria, Australia

Search for other papers by Mario De Luise in
Google Scholar
PubMed
Close
, and
Ego Seeman Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Ego Seeman in
Google Scholar
PubMed
Close

Summary

ACTH-secreting phaeochromocytoma (ASP) is a rare cause of ACTH-dependent Cushing’s syndrome (CS). We report the case of a 63-year-old female presenting with CS secondary to an ASP complicated by bowel perforation. This case report highlights ASP as an uncommon but important cause of ectopic ACTH secretion (EAS). There have been 29 cases of ASP, all of which were unilateral and benign, but associated with significant complications. Patients presenting with ASP have the potential for cure with unilateral adrenalectomy. Given this promising prognosis if recognised, ASP should be considered in the diagnostic workup of ACTH-dependent CS. As this case demonstrates, gastrointestinal complications can arise from severe hypercortisolaemia associated with CS. Early medical and surgical intervention is imperative as mortality approaches 50% once bowel perforation occurs.

Learning points

  • Consider phaeochromocytoma in the diagnostic workup of ACTH-dependent CS; screen with plasma metanephrines or urinary catecholamines.

  • Serial screening may be required if ACTH-secreting phaeochromocytoma is suspected, as absolute levels can be misleading.

  • Early catecholamine receptor blockade and adrenal synthesis blockade may avoid the need for rescue bilateral adrenalectomy in ACTH-secreting phaeochromocytoma.

  • Consider early medical or surgical management when gastrointestinal features are present in patients with CS, as bowel perforation due to severe hypercortisolaemia can occur and is associated with significant mortality.

Open access
Marco Russo Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

Search for other papers by Marco Russo in
Google Scholar
PubMed
Close
,
Ilenia Marturano Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Ilenia Marturano in
Google Scholar
PubMed
Close
,
Romilda Masucci Surgical Oncology, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Romilda Masucci in
Google Scholar
PubMed
Close
,
Melania Caruso Gynecology and Obstetrics, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Melania Caruso in
Google Scholar
PubMed
Close
,
Maria Concetta Fornito Nuclear Medicine, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Maria Concetta Fornito in
Google Scholar
PubMed
Close
,
Dario Tumino Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Dario Tumino in
Google Scholar
PubMed
Close
,
Martina Tavarelli Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Martina Tavarelli in
Google Scholar
PubMed
Close
,
Sebastiano Squatrito Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Sebastiano Squatrito in
Google Scholar
PubMed
Close
, and
Gabriella Pellegriti Endocrinology, Garibaldi-Nesima Hospital, Catania, Italy

Search for other papers by Gabriella Pellegriti in
Google Scholar
PubMed
Close

Summary

Struma ovarii is a rare ovarian teratoma characterized by the presence of thyroid tissue as the major component. Malignant transformation of the thyroidal component (malignant struma ovarii) has been reported in approximately 5% of struma ovarii. The management and follow-up of this unusual disease remain controversial. We report the case of a woman with a history of autoimmune thyroiditis and a previous resection of a benign struma ovarii that underwent hystero-annexiectomy for malignant struma ovarii with multiple papillary thyroid cancer foci and peritoneal involvement. Total thyroidectomy and subsequent radioiodine treatment lead to complete disease remission after 104 months of follow-up. The diagnosis and natural progression of malignant struma ovarii are difficult to discern, and relapses can occur several years after diagnosis. A multidisciplinary approach is mandatory; after surgical excision of malignant struma, thyroidectomy in combination with 131I therapy should be considered after risk stratification in accordance with a standard approach in differentiated thyroid cancer patients.

Learning points

  • Malignant struma ovarii is a rare disease; diagnosis is difficult and management is not well defined.

  • Predominant sites of metastasis are adjacent pelvic structures.

  • Thyroidectomy and 131I therapy should be considered after risk stratification in accordance with standard approaches in DTC patients.

Open access